GlassScriptPhysician profile
Elora D Pliska
NPI 1609316371
$1,427.27
in general payments reported to CMS, 2019-2025
21 companies · $25.67 in 2025
The $25.67 reported for 2025 was less than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $793 · 2023: $609 · 2025: $25.67.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $634.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $634.42 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $268.21 | 2022-2023 | Repatha, Otezla, Evenity |
| Lilly USA, LLC | $234.53 | 2022-2023 | Mounjaro, Jardiance, Emgality |
| Novo Nordisk INC | $161.21 | 2022-2023 | Rybelsus, Ozempic |
| Abbvie INC. | $144.13 | 2022-2023 | |
| Janssen Pharmaceuticals, INC | $95.88 | 2022-2023 | Spravato |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $76.70 | 2022-2023 | Xifaxan, Trulance |
| Astrazeneca Pharmaceuticals LP | $70.87 | 2022 | |
| Pfizer INC. | $50.61 | 2022-2023 | |
| Novartis Pharmaceuticals Corporation | $44.19 | 2023 | |
| Biohaven Pharmaceutical Holding Company LTD. | $43.11 | 2022 | |
| Otsuka America Pharmaceutical, INC. | $35.32 | 2022-2023 | Rexulti |
| Bayer Healthcare Pharmaceuticals INC. | $33.37 | 2022-2023 | |
| Kowa Pharmaceuticals America, INC. | $30.05 | 2022-2023 | Livalo, Seglentis |
| Boehringer Ingelheim Pharmaceuticals, INC. | $25.67 | 2025 | Jardiance |
| Vbi Vaccine (Delaware) INC. | $20.22 | 2022 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $18.69 | 2023 | Eliquis |
| Corium, LLC | $17.57 | 2023 | Azstarys |
| Daiichi Sankyo INC. | $15.27 | 2023 | Injectafer |
| Collegium Pharmaceutical, INC. | $14.97 | 2023 | Belbuca |
| Sanofi-Aventis U.S. LLC | $14.23 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $12.47 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Elora Pliska listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.